Skip to main content
. 2021 Jan 18;12:424. doi: 10.1038/s41467-020-20731-x

Fig. 2. Country-wise contribution to vaccine-avertable incidence of RR-TB.

Fig. 2

The area of each square is proportional to the median estimate from n = 200 posterior samples, for the absolute number of avertable rifampicin-resistant tuberculosis (RR-TB) cases by a post-exposure, M72-like vaccine, between 2020 and 2035. Panel a shows cases averted by a vaccine alone, while panel b shows cases averted by a combination of a vaccine and measures to improve the management of RR-TB (both relative to a scenario of no vaccine, and no improvement in RR-TB, i.e. status quo). Countries are denoted by their ISO alpha-3 codes and their corresponding full names are listed in Table 1. Colours for each country are only for the purpose of display, and do not designate any quantitative scale.